Skip to content

XOMA Corporation XOMA Business Segments — Gain Loss On Contract Termination

Similar metrics at other companies

Scholar Rock logo
SRRKSingle Reportable — Gain Loss On Disposition Of Assets
-$3K
Cracker Barrel Old Country Store logo
CBRLSingle Reportable — Gain Loss Related To Litigation Settlement
$47.42M
Kulicke & Soffa Industries logo
KLICGain Loss On Contract Termination
$0
InvenTrust Properties logo
IVTReportable Segment — Gain (Loss) on Termination of Lease
$0+100%
Mama's Creations, Inc. logo
MAMAGain Loss On Contract Termination
$0-100%
Adient logo
ADNTGain Loss On Contract Termination
$2M0.0%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnContractTermination.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's business segments — gain loss on contract termination.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's business segments — gain loss on contract termination?
XOMA Corporation (XOMA) reported business segments — gain loss on contract termination of $27K in Q1 2026.
What does business segments — gain loss on contract termination mean?
Represents the financial impact resulting from the early conclusion or modification of royalty agreements or licensing contracts. This metric highlights the volatility associated with the lifecycle of individual biotech assets and the company's contractual relationships.